Cohance Lifesciences shares surge 43% in two sessions.

Cohance Lifesciences shares surge 43% in two sessions. The pharmaceutical company's stock rally follows the appointment of Umang Vohra, former Cipla CEO, as Executive Chairman and Group CEO effective next month. Vohra brings over three decades of industry experience and successfully transformed Cipla into a diversified global pharmaceutical enterprise. The market has responded positively to this leadership change, viewing it as a strategic move to accelerate Cohance's transformation and growth trajectory. Vohra will replace Vivek Sharma, who steps down for personal reasons but remains as advisor for nine months. Analysts attribute the surge to investor confidence in Vohra's proven track record in operational excellence and business transformation. Cohance operates in the competitive CDMO market with specialized capabilities in complex APIs and advanced process research and development.